Trial reportDiabetes, obesity & metabolism2026
Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo-Controlled, Double-Blind, Crossover Study.
Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionOxytocin is expressed throughout the small intestine, suggesting a role for oxytocin in postprandial metabolism. Accordingly, single-dose intranasal oxytocin reduces food intake and improves glucose tolerance. We investigated the effects of a continuous intravenous oxytocin infusion on ad libitum food intake, appetite sensations, and postprandial metabolism.
methodsIn a randomised, placebo-controlled, double-blind, crossover study, overnight fasted participants with obesity underwent two 4.5-hour intravenous infusions of oxytocin (0.2 international units/min) and placebo (saline), respectively, on separate days interposed by a wash-out period of a minimum of seven days. After 60 min of infusion, participants ingested a standardised liquid mixed meal containing 1.5 g paracetamol (for evaluation of gastric emptying). Appetite sensations were assessed by visual analogue scales, and concentrations of plasma glucose as well as glucose and appetite-regulating hormones were measured. After four hours, food intake (primary endpoint) was assessed by an ad libitum meal test.
resultsTwenty-four individuals (12 women, median age 41.5 (interquartile range (IQR) 28.5;55.3) years, body mass index 36.2 (32.1;37.6) kg/m
conclusionIn individuals with obesity, 4.5-hour intravenous infusion of oxytocin causing supraphysiological plasma concentrations of ~400 pg/mL has no effect on ad libitum food intake, appetite sensations, plasma glucose levels, circulating concentrations of glucose and appetite-regulating hormones, or gastric emptying.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.